SINGLE-NUCLEOTIDE POLYMORPHISMS OF CALCIUM-SENSING RECEPTOR ENCODING GENE ASSOCIATED WITH CALCIUM KIDNEY STONE DISEASE IN BABYLON PROVINCE
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i2.22064Keywords:
Chronic and end-stage renal disease, Polymerase chain reaction, rs1801725, Calcium-sensing receptor, Single-nucleotide polymorphismsAbstract
Â
 Objective: The calcium-sensing receptor (CASR) is a G-protein-coupled receptor that is mainly expressed in the parathyroid and the kidneys where it regulates parathyroid hormone secretion and renal tubular calcium reabsorption. Inactivating and activating CASR gene due to mutations severally caused hypercalcemia or hypocalcemia disorders. The aim of the study was to investigate the risk factor of CASR rs1801725 (Ala986Ser) patients with renal disease.
Method: The blood samples were collected from 100 patients and divided into two groups, each one containing 50 samples; chronic kidney disease and end-stage renal disease, who admitted Merjan Teaching Hospital in Babylon Province, Iraq, from February to July 2016. In addition, healthy persons as a control group (50 samples). Genotyping of CASR single-nucleotide polymorphisms (SNP) was performed using a polymerase chain reaction technique, followed by single-strand conformation polymorphism. Accordingly, these DNA polymorphisms were confirmed using DNA sequencing.
Results: The conformational haplotypes of CASR, exon7 NCBI Primer3plus reference were obtained in three patterns, including two, three, and four bands, due to the presence SNPs within the studied region. These SNPs leads to change three amino acid residues of CASR, including amino acid substitutions were Ala 128→ Ser 128, Leu 155→Tye 155, and Leu 156→ Ser 156 that may affect or modified the tertiary structure of the receptor, subsequently the function like the affinity to calcium ion may be effected.
Conclusion: These results suggest that the variants of CASR SNP, namely, rs1801725 might be involved in susceptibility to kidney stone disease.
Downloads
References
Guha M, Bankura B, Ghosh S, Pattanayak AK, Ghosh S, Pal DK, et al. Polymorphisms in CaSR and CLDN14 genes associated with increased risk of kidney stone disease in patients from the Eastern Part of India. PLoS One 2015;10:e0130790.
Devuyst O, Pirson Y. Genetics of hypercalciuric stone forming diseases. Kidney Int 2007;72:1065-72.
Brown EM, Hebert SC. A cloned Ca2+sensing receptor: A mediator of direct effects of extracellular Ca2+ on renal function. J Am Soc Nephrol 1995;6:1530-40.
Brown EM, Hebert SC. Calcium receptor regulated parathyroid and renal function. Bone 1997;20:303-9.
Scillitani A, Guarnieri V, Battista C, De Geronimo S, Muscarella LA, Chiodini I, et al. Primary hyperparathyroidism and the presence of kidney stones are associated with different haplotypes of the calciumsensing receptor. J Clin Endocrinol Metab 2007;92:277-83.
Cole DE, Peltekova VD, Rubin LA, Hawker GA, Virth R, Liew CC, et al. A986S polymorphism of the calciumsensing receptor and circulating calcium concentrations. Lancet 1998;353:112-5.
Vezzoli G, Terranegra A, Arcidiacono T, Biasion R, Coviello D, Syren ML, et al. R990G polymorphism of calciumsensing receptor does produce gainoffunctionand predispose to primary hypercalciuria. Kidney Int 2007;71:1155-62.
Hamilton DC, Grover VK, Smith CA, Cole DE. Heterogeneous disease modeling for hardy-weinberg disequilibrium in case-control studies: Application to renal stones and calciumsensing receptor polymorphisms. Ann Hum Genetics 2009;73:176-83.
Harding B, Curley AJ, Hannan FM, Christie PT, Bowl MR, Turner JJ, et al. Functional characterization of calciumsensing receptor polymorphisms and absence of association with indices of calcium homeostasis and bone mineral density. Clin Endocrinol 2006;65:598-5.
Seyhan S, Yavascaoglu I, Kilicarslan H, Dogan HS, Kordan Y. Association of vitamin D receptor gene Taq I polymorphism with recurrent urolithiasis in children. Int J Urol 2007;14:1060-2.
Heilberg IP, Goldfarb DS. Optimum nutrition for kidney stone disease.
Adv Chronic Kidney Dis 2013;20:165-74.
Vezzoli G, Terranegra A, Soldati L. Calciumsensing receptor gene polymorphisms in patients with calcium nephrolithiasis. Curr Opin Nephrol Hypertens 2012;21:355-61.
Gunes S, Bilen CY, Kara N, Asci R, Bagci H, Yilmaz AF. Vitamin D receptor gene polymorphisms in patients with urolithiasis. Urol Res 2006;34:47-52.
Ferreira LG, Pereira AC, Heilberg IP. Vitamin D receptor and calciumsensing receptor gene polymorphisms in hypercalciuric stoneforming patients. Nephron Clin Pract 2009;114:135-44.
Yao JJ, Bai S, Karnauskas AJ, Bushinsky DA, Favus MJ. Regulation of renal calcium receptor gene expression by 1,25dihydroxyvitamin D3 in genetic hypercalciuricstoneforming rats. J Am Soc Nephrol 2005;16:1300-8.
Dimke H, Desai P, Borovac J, Lau A, Pan W, Alexander RT. Activation of the Ca2+sensing receptor increases renal claudin14 expression and urinary Ca2+excretion. Am J Physiol Renal Physiol 2013;304:F761-9.
O’Seaghdha CM, Yang Q, Glazer NL, Leak TS, Dehghan A, Smith AV, et al. Common variants in the calciumsensing receptor gene are associated with total serum calcium levels. Hum Mol Genet 2010;19:4296-303.
Gambaro G, Soldati L, Vezzoli G. Genetics and molecular biology of renal stones. In: Rao PN, Preminger GM, Kavanagh JP, editors. Urinary Tract Stone Disease. London: Springer-Verlag London Limited.; 2011. p. 9-15.
Thiyagara A, Sunny JS, Hopper W. Effect of toll-like receptor inhibitor imiquimod on IL1R1 interaction with IL-1RA and ITS variant-an in silico approach. Int J Pharm Pharm Sci 2016;8:109-12.
Murthy VB, Chowdary M, Sucharitha I. In silico prediction of deleterious and non-deleterious nsSNPs in CFTR gene variants. Int J Pharm Pharm Sci 2016;8:303-6.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
